RankAlpha logo
Back to Rankings

ERAS

ErascaD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
View Chart
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
ERAS vs peer average
45/100
ERAS vs. peer average (D vs. D)
Grade spread
C 4 · D 5 · F 1
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

RVMD is the first available peer comparator.

Most relevant operating read-through because Erasca’s 8-K explicitly benchmarked ERAS-0015 against Revolution Medicines comparator data; useful for judging whether ERAS-0015 is differentiated enough to justify valuation recovery.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerRVMDRevolution Medicines
ERAS
Erasca
RVMD
Revolution Medicines
Grade
D
D
Momentum
99
93
Value
41
41
Sentiment
0
19
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Open Side-by-Side ComparisonCompare all

Grade position vs RVMD

ERAS / RVMD
Grade Position
In line
ERAS vs. peer average (D vs. D)
45/100
Momentum
99
ERAS
Value
41
ERAS
Sentiment
0
RVMD

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs ERAS
1
RVMD
RVMD
D
40/100
Even
2
IOVA
IOVA
D
40/100
Even
3
COGT
Cogent Biosciences Inc Common
F
20/100
+1
4
GRFS
Grifols SA Class B ADR
D
40/100
Even
5
MIRM
Mirum Pharmaceuticals Inc Common
C
60/100
-1
RVMD is the first peer returned for this comparison set.